The Centre for Antimicrobial Optimisation (CAMO) brings together innovative, multidisciplinary research to optimise antimicrobial use and sustain the effectiveness of these drugs in the face of increasing antimicrobial resistance (AMR) and the absence of new treatments. Currently, existing antimicrobials are not being used effectively. Antimicrobial prescribing is rather rigid and based on a static ‘one dose fits all’ model which doesn’t account for wide variations in how different bodies process the drug (e.g. in obesity, and when receiving other medicines). This variability influences drug levels achieved, and therefore effectiveness and risk of side effects. Nor does it account for wide variations in how this processing may change over time within an individual in different clinical situations (e.g. sepsis). Appropriate dosing for specific organisms, resistance patterns, infections and clinical scenarios is frequently not achieved. Consequently, treatment is often suboptimal, affecting clinical outcomes and driving AMR.

The creation of this centre of excellence provides a state-of-the-art research facility to support the creative development of technology to optimise antimicrobial use. This will enable us to achieve tailored dosing for the individual, organism and infection and to explore how we can do this non-invasively, in real time.

CAMO consolidates existing expertise at Imperial, addressing new frontiers in AMR research. It encompasses an unparalleled combination of expertise within data science, artificial intelligence, chemistry, biosensors, engineering and infectious diseases, all working with clinicians and the Clinical Research Facility to ensure the delivery of novel solutions, co-designed with end users and patients to optimise antimicrobial use for patient and societal benefit.